As part of its Community Case Forum series, key opinion leaders and participants discuss the use of CAR T-cell therapy for the treatment of patients with multiple myeloma.
Caregivers, Clinicians Must Be Familiar With CRS Risk After CAR T-Cell Therapy
At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell therapy.
Advancing Multiple Myeloma Treatment With CAR T-Cell Therapy
Daniel Verina, DNP, ACNP-BC, discussed how CAR T-cell therapy is changing the treatment landscape for patients with multiple myeloma.
Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer
Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care
T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations
AI Tool May Predict Response, Resistance in Advanced RCC